Antibody engineering

Annual Review of Biomedical Engineering

Volumn 2, Issue 2000, 2000, Pages 339-376

  Maynard, Jennifer ^a   Georgiou, George ^a,b  

^a The University of Texas at Austin   (United States)

^b UNIVERSITY OF TEXAS AT AUSTIN   (United States)

Author keywords

Antigen; Combinatorial libraries; Library screening; Phage display; scFv

Indexed keywords

ANTIBODY; PEPTIDE LIBRARY; RECOMBINANT PROTEIN;

ANIMAL; ANTIBODY AFFINITY; BIOMEDICAL ENGINEERING; CHEMICAL STRUCTURE; CHEMISTRY; GENETICS; HUMAN; IMMUNOLOGY; METHODOLOGY; MOLECULAR CLONING; MOUSE; NEOPLASM; PROTEIN ENGINEERING; REVIEW; TRANSGENIC MOUSE;

ANIMALS; ANTIBODIES; ANTIBODY AFFINITY; BIOMEDICAL ENGINEERING; CLONING, MOLECULAR; HUMANS; MICE; MICE, TRANSGENIC; MODELS, MOLECULAR; NEOPLASMS; PEPTIDE LIBRARY; PROTEIN ENGINEERING; RECOMBINANT PROTEINS;

EID: 0034575023     PISSN: 15239829     EISSN: None     Source Type: Book Series    
DOI: 10.1146/annurev.bioeng.2.1.339     Document Type: Article

References (235)

1. Jeffrey PD, Strong RK, Sieker LC, Chang CY, Campbell RL, et al. 1993. 26-10 Fabdigoxin complex: affinity and specificity due to surface complementarity. Proc. Natl. Acad. Sci. USA 90:10310-14
2. Holliger P, Hoogenboom H. 1998. Antibodies come back from the brink. Nat. Biotechnol. 16:1015-16
3. Kuby J. 1997. Immunology. New York: Freeman. 664 pp.
4. Crottet P, Cottet S, Corthesy B. 1999. Expression, purification and biochemical characterization of recombinant murine secretory component: a novel tool in mucosal immunology. Biochem. J. 341:299-306
5. Ma JK, Hiatt A, Hein M, Vine ND, Wang F, et al. 1995. Generation and assembly of secretory antibodies in plants. Science 268:716-19
6. MacCallum RM, Martin AC, Thornton JM. 1996. Antibody-antigen interactions: contact analysis and binding site topography. J. Mol. Biol. 262:732-45
7. Braden BC, Goldman ER, Mariuzza RA, Poljak RJ. 1998. Anatomy of an antibody molecule: structure, kinetics, thermodynamics and mutational studies of the anti-lysozyme antibody D1.3. Immunol. Rev. 163:45-57
8. Bhat TN, Bentley GA, Boulot G, Greene MI, Tello D, et al. 1994. Bound water molecules and conformational stabilization help mediate an antigen-antibody association. Proc. Natl. Acad. Sci. USA 91:1089-93
9. Jin L, Wells JA. 1994. Dissecting the energetics of an antibody-antigen interface by alanine shaving and molecular grafting. Protein Sci. 3:2351-57
10. Clackson T, Wells JA. 1995. A hot spot of binding energy in a hormone-receptor interface. Science 267:383-86
11. Kohler G, Milstein C. 1975. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 256:495-98
12. Winter G, Milstein C. 1991. Man-made antibodies. Nature 349:293-99
13. Pluckthun A, Skerra A. 1989. Expression of functional antibody Fv and Fab fragments in Escherichia coli. Methods Enzymol. 178:497-515
14. Benhar I, Pastan I. 1994. Cloning, expression, and characterization of the Fv fragments of the anti-carbohydrate mAbs B1 and B5 as single chain immunotoxins. Protein Eng. 7:1509-15
15. Ruberti F, Cattaneo A, Bradbury A. 1994. The use of the RACE method to clone hybridoma cDNA when V region primers fail. J. Immunol. Methods 173:33-39
16. Larrick JW, Danielsson L, Brenner CA, Abrahamson M, Fry KE, et al. 1989. Rapid cloning of rearranged immunoglobulin genes from human hybridoma cells using mixed primers and the polymerase chain reaction. Biochem. Biophys. Res. Commun. 160:1250-56
17. Kabat EA, Wu TT, Reid-Miller M, Perry HM, Gottesman KS, eds. 1991. Sequences of Proteins of Immunological Interest. Bethesda, MD: US Dep. Health Hum. Serv. 5th ed.
18. Orlandi R, Gussow DH, Jones PT, Winter G. 1989. Cloning immunoglobulin variable domains for expression by the polymerase chain reaction. Proc. Natl. Acad. Sci. USA 86:3833-37
19. Sblattero D, Bradbury A. 1998. A definitive set of oligonucleotide primers for amplifying human V regions. Immunotechnology 3:271-78
20. Krebber A, Bornhauser S, Burmester J, Honegger A, Willuda J, et al. 1997. Reliable cloning of functional antibody variable domains from hybridomas and spleen cell repertoires employing a reengineered phage display system. J. Immunol. Methods 201:35-55
21. Cabilly S, Cabilly AD. 1985. Immunoglobulin transcripts and molecular history of a hybridoma that produces antibody to carcinoembryonic antigen. Gene 40:157-61
22. Carroll WF, Mendel E, Levy S. 1988. Hybridoma fusion cell lines contain an aberrant kappa transcript. Mol. Immunol. 25:991-95
23. Duan L, Pomerantz RJ. 1994. Elimination of endogenous aberrant kappa chain transcripts from sp2/0-derived hybridoma cells by specific ribozyme cleavage: utility in genetic therapy of HFV-1 infections. Nucleic Acids Res. 22:5433-38
24. de Haard H, Kazemier B, van der Bent A, Oudshoorn P, Boender P, et al. 1999. Vernier zone residue 4 of mouse sub-group II kappa light chains is a critical determinant for antigen recognition. Immunotechnology 4:203-15
25. Hamers-Casterman C, Atarhouch T, Muyldermans S, Robinson G, Hamers C, et al. 1993. Naturally occurring antibodies devoid of light chains. Nature 363:446-48
26. Desmyter A, Transue TR, Ghahroudi MA, Thi MH, Poortmans F, et al. 1996. Crystal structure of a camel single-domain VH antibody fragment in complex with lysozyme. Nat. Struct. Biol. 3:803-11
27. Decanniere K, Desmyter A, Lauwereys M, Ghahroudi MA, Muyldermans S, et al. 1999. A single-domain antibody fragment in complex with RNase A: non-canonical loop structures and nanomolar affinity using two CDR loops. Structure 7:361-70
28. Davies J, Riechmann L. 1994. 'Camelising' human antibody fragments: NMR studies on VH domains. FEBS Lett. 339: 285-90
29. Davies J, Riechmann L. 1996. Single antibody domains as small recognition units: design and in vitro antigen selection of camelized, human VH domains with improved protein stability. Protein Eng. 9: 531-37
30. Kortt AA, Guthrie RE, Hinds MG, Power BE, Ivancic N, et al. 1995. Solution properties of Escherichia coli-expressed VH domain of anti-neuraminidase antibody NC41. J. Protein Chem. 14:167-78
31. Reiter Y, Schuck P, Boyd LF, Plaksin D. 1999. An antibody single-domain phage display library of a native heavy chain variable region: isolation of functional single-domain VH molecules with a unique interface. J. Mol. Biol. 290:685-98
32. Huston JS, Levinson D, Mudgett-Hunter M, Tai MS, Novotny J, et al. 1988. Protein engineering of antibody binding sites: recovery of specific activity in an anti-digoxin single-chain Fv analogue produced in Escherichia coli. Proc. Natl. Acad. Sci. USA 85:5879-83
33. Tsumoto K, Nakaoki Y, Ueda Y, Ogasahara K, Yutani K, et al. 1994. Effect of the order of antibody variable regions on the expression of the single chain HyHe110 Fv fragment in E. coli and the thermodynamic analysis of its antigen-binding properties. Biochem. Biophys. Res. Commun. 201:546-51
34. Merk H, Stiege W, Tsumoto K, Kumagai I, Erdmann VA. 1999. Cell-free expression of two single chain monoclonal antibodies against lysozyme: effect of domain arrangement on the expression. J. Biochem. 125:328-33
35. Takkinan K, Laukkanen M-L, Sizmann D, Alfthan K, Immonen T, et al. 1991. An active single-chain antibody containing a cellulase linker domain is secreted by Escherichia coli. Protein Eng. 4:837-41
36. Pantoliano M, Bird RE, Johnson S, Asel ED, Dodd SW, et al. 1991. Conformational stability, folding, and ligand-binding affinity of single-chain Fv immunoglobulin fragments expressed in Escherichia coli. Biochemistry 30:10117-25
37. Tang Y, Jiang N, Parakh C, Hilvert D. 1996. Selection for linkers for a catalytic single-chain antibody using phage display technology. J. Biol. Chem. 271:15682-86
38. Turner DJ, Ritter MA, George AJ. 1997. Importance of the linker in expression of single-chain Fv antibody fragments: optimisation of peptide sequence using phage display technology. J. Immunol. Methods 205:43-54
39. Robinson C, Sauer R. 1998. Optimizing the stability of single chain proteins by linker length and compositional mutagenesis. Proc. Natl. Acad. Sci. USA 95:5929-34
40. Hennecke F, Krebber C, Pluckthun A. 1998. Non-repetitive single-chain Fv linkers selected by selectively infective phage (SIP) technology. Protein Eng. 11:405-10
41. Carter P, Kelley RF, Rodrigues ML, Snedecor B, Covarrubias M, et al. 1992. High level Escherichia coli expression and production of a bivalent humanized antibody fragment. Bio-Technology 10:163-67
42. Skerra A. 1994. A general vector, pASK84, for cloning, bacterial production, and single-step purification of antibody Fab fragments. Gene 141:79-84
43. Neri D, Montigiani S, Kirkham PM. 1996. Biophysical methods for the determination of antibody-antigen affinities. Trends Biotechnol. 14:465-70
44. Lakey JH, Raggett EM. 1998. Measuring protein-protein interactions. Curr. Opin. Struct. Biol. 8:119-23
45. Friguet B, Chaffotte AF, Djavadi-Ohaniance L, Goldberg ME. 1985. Measurements of the true affinity constant in solution of antigen-antibody complexes by enzyme-linked immunosorbent assay. J. Immunol. Methods 77:305-19
46. Livingstone JR. 1996. Antibody characterization by isothermal titration calorimetry. Nature 384:491-92
47. Boder ET, Wittrup KD. 1997. Yeast surface display for screening combinatorial polypeptide libraries. Nat. Biotechnol. 15: 553-57
48. Daugherty PS, Chen G, Olsen MJ, Iverson BL, Georgiou G. 1998. Antibody affinity maturation using bacterial surface display. Protein Eng. 11:825-32
49. Daugherty P, Iverson B, Georgiou G. 2000. Flow cytometric screening of cell-based libraries. J. Immunol. Methods. In press
50. Fivash M, Towler E, Fisher R. 1998. BIAcore for macromolecular interactions. Curr. Opin. Biotechnol. 9:97-101
51. Malmborg AC, Borrebaeck CA. 1995. BIAcore as a tool in antibody engineering. J. Immunol. Methods 183:7-13
52. Nieba L, Krebber A, Pluckthun A. 1996. Competition BIAcore for measuring true affinities: large differences from values determined from binding kinetics. Anal. Biochem. 234:155-65
53. Malmborg AC, Duenas M, Ohlin M, Soderlind E, Borrebaeck CA. 1996. Selection of binders from phage displayed antibody libraries using the BIAcore biosensor. J. Immunol. Methods 198:51-57
54. Kazemier B, de Haard H, Boender P, van Gemen B, Hoogenboom H. 1996. Determination of active single chain antibody concentrations in crude periplasmic fractions. J. Immunol. Methods 194:201-9
55. Deleted in proof
56. Winter G, Griffiths AD, Hawkins RE, Hoogenboom HR. 1994. Making antibodies by phage display technology. Annu. Rev. Immunol. 12:433-55
57. Hoogenboom HR, de Bruine AP, Hufton SE, Hoet RM, Arends JW, et al. 1998. Antibody phage display technology and its applications. Immunotechnology 4:1-20
58. Shusta EV, VanAntwerp J, Wittrup KD. 1999. Biosynthetic polypeptide libraries. Curr. Opin. Biotechnol. 10:117-22
59. Huse WD, Sastry L, Iverson SA, Kang AS, Alting-Mees M, et al. 1989. Generation of a large combinatorial library of the immunoglobulin repertoire in phage lambda. Science 246:1275-81
60. Wu H, Nie Y, Huse WD, Watkins JD. 1999. Humanization of a murine monoclonal antibody by simultaneous optimization of framework and CDR residues. J. Mol. Biol. 294:151-62
61. Hawkins RE, Russell SJ, Winter G. 1992. Selection of phage antibodies by binding affinity. Mimicking affinity maturation. J. Mol. Biol. 226:889-96
62. Duenas M, Borrebaeck CA. 1994. Clonal selection and amplification of phage displayed antibodies by linking antigen recognition and phage replication. Bio-Technology 12:999-1002
63. Spada S, Krebber C, Pluckthun A. 1997. Selectively infective phages (SIP). Biol. Chem. 378:445-56
64. Hill HR, Stockley PG. 1996. Phage presentation. Mol. Microbiol. 20:685-92
65. Rodi DJ, Makowski L. 1999. Phage display technology - finding a needle in a vast molecular haystack. Curr. Opin. Biotechnol. 10:87-93
66. Griffiths AD, Duncan AR. 1998. Strategies for selection of antibodies by phage display. Curr. Opin. Biotechnol. 9:102-8
67. Fuchs P, Breitling F, Dubel S, Seehaus T, Little M. 1991. Targeting recombinant antibodies to the surface of Escherichia coli: fusion to a peptidoglycan associated lipoprotein. Bio-Technology 9:1369-72
68. Francisco JA, Campbell R, Iverson BL, Georgiou G. 1993. Production and fluorescence-activated cell sorting of Escherichia coli expressing a functional antibody fragment on the external surface. Proc. Natl. Acad. Sci. USA 90:10444-48
69. Gunneriusson E, Samuelson P, Uhlen M, Nygren PA, Stahl S. 1996. Surface display of a functional single-chain Fv antibody on staphylococci. J. Bacteriol. 178:1341-46
70. Georgiou G, Stathopoulos C, Daugherty PS, Nayak AR, Iverson BL, et al. 1997. Display of heterologous proteins on the surface of microorganisms: from the screening of combinatorial libraries to live recombinant vaccines. Nat. Biotechnol. 15: 29-34
71. Daugherty P, Chen G, Iverson B, Georgiou G. 2000. Quantitative analysis of the effect of the mutation frequency on the affinity maturation of antibodies. Proc. Natl. Acad. Sci. USA. In press
72. Deleted in proof
73. Burks EA, Chen G, Georgiou G, Iverson BL. 1997. In vitro scanning saturation mutagenesis of an antibody binding pocket. Proc. Natl. Acad. Sci. USA 94:412-17
74. Chen G, Dubrawsky I, Mendez P, Georgiou G, Iverson BL. 1999. In vitro scanning saturation mutagenesis of all the specificity determining residues in an antibody binding site. Protein Eng. 12:349-56
75. Deleted in proof
76. Roberts RW. 1999. Totally in vitro protein selection using mRNA-protein fusions and ribosome display. Curr. Opin. Chem. Biol. 3:268-73
77. Mattheakis LC, Bhatt RR, Dower WJ. 1994. An in vitro polysome display system for identifying ligands from very large peptide libraries. Proc. Natl. Acad. Sci. USA 91:9022-26
78. Hanes J, Jermutus L, Weber-Bornhauser S, Bosshard HR, Pluckthun A. 1998. Ribosome display efficiently selects and evolves high-affinity antibodies in vitro from immune libraries. Proc. Natl. Acad. Sci. USA 95:14130-35
79. Hanes J, Pluckthun A. 1999. In vitro selection methods for screening of peptide and protein libraries. Curr. Top. Microbiol. Immunol. 243:107-22
80. He M, Taussig MJ. 1997. Antibody-ribosome-mRNA (ARM) complexes as efficient selection particles for in vitro display and evolution of antibody combining sites. Nucleic Acids Res. 25:5132-34
81. Roberts R, Szostak JW. 1997. RNA-peptide fusions for the in vitro selection of peptides and proteins. Proc. Natl. Acad. Sci. USA 94:12297-302
82. Neuberger MS, Ehrenstein MR, Klix N, Jolly CJ, Yelamos J, et al. 1998. Monitoring and interpreting the intrinsic features of somatic hypermutation. Immunol. Rev. 162:107-16
83. Wabl M, Cascalho M, Steinberg C. 1999. Hypermutation in antibody affinity maturation. Curr. Opin. Immunol. 11:186-89
84. Barbas CF III, Burton DR. 1996. Selection and evolution of high-affinity human anti-viral antibodies. Trends Biotechnol. 14:230-34
85. Persson MA, Caothien RH, Burton DR. 1991. Generation of diverse high-affinity human monoclonal antibodies by repertoire cloning. Proc. Natl. Acad. Sci. USA 88:2432-36
86. Emanuel P, O'Brien T, Burans J, DasGupta BR, Valdes JJ, et al. 1996. Directing antigen specificity towards botulinum neurotoxin with combinatorial phage display libraries. J. Immunol. Methods 193:189-97
87. Cai XH, Garen A. 1997. Comparison of fusion phage libraries displaying Vh of single chain Fv antibody fragments derived from the antibody repertoire of a vaccinated melanoma patient as a source of melanoma-specific targeting molecules. Proc. Natl. Acad. Sci. USA 94:9261-66
88. Chowdhury PS, Viner JL, Beers R, Pastan I. 1998. Isolation of a high-affinity stable single-chain Fv specific for mesothelin from DNA-immunized mice by phage display and construction of a recombinant immunotoxin with anti-tumor activity. Proc. Natl. Acad. Sci. USA 95:669-74
89. Mao S, Gao C, Lo CH, Wirsching P, Wong CH, et al. 1999. Phage-display library selection of high-affinity human single-chain antibodies to tumor-associated carbohydrate antigens sialyl Lewisx and Lewisx. Proc. Natl. Acad. Sci. USA 96:6953-58
90. Vaughan TJ, Williams AJ, Pritchard K, Osbourn JK, Pope AR, et al. 1996. Human antibodies with sub-nanomolar affinities isolated from a large non-immunized phage display library. Nat. Biotechnol. 14: 309-14
91. Marks JD, Hoogenboom HR, Bonnert TP, McCafferty J, Griffiths AD, et al. 1991. Bypassing immunization. Human antibodies from V-gene libraries displayed on phage. J. Mol. Biol. 222:581-97
92. Griffiths AD, Malmqvist M, Marks JD, Bye JM, Embleton MJ, et al. 1993. Human anti-self antibodies with high specificity from phage display libraries. EMBO J. 12:725-34
93. Xie M-H, Yuan J, Adams C, Gurney A. 1997. Direct demonstration of MuSK involvement in acetylcholine receptor clustering through identification of agonist scFv. Nat. Biotechnol. 15:768-71
94. Winter G. 1998. Synthetic human antibodies and a strategy for protein engineering. FEBS Lett. 430:92-94
95. Hoogenboom HR, Winter G. 1992. Bypassing immunisation. Human antibodies from synthetic repertoires of germline VH gene segments rearranged in vitro. J. Mol. Biol. 227:381-88
96. Nissim A, Hoogenboom HR, Tomlinson IM, Flynn G, Midgley C, et al. 1994. Antibody fragments from a 'single pot' phage display library as immunochemical reagents. EMBO J. 13:692-98
97. Griffiths AD, Williams SC, Hartley O, Tomlinson IM, Waterhouse P, et al. 1994. Isolation of high affinity human antibodies directly from large synthetic repertoires. EMBO J. 13:3245-60
98. de Kruif J, Boel E, Logtenberg T. 1995. Selection and application of human single chain Fv antibody fragments from a semi-synthetic phage antibody display library with designed CDR3 regions. J. Mol. Biol. 248:97-105
99. Barbas CF, Bain JD, Hoekstra DM, Lerner RA. 1992. Semisynthetic combinatorial antibody libraries: a chemical solution to the diversity problem. Proc. Natl. Acad. Sci. USA 89:4457-61
100. de Wildt RM, Finnern R, Ouwehand WH, Griffiths AD, van Venrooij WJ, et al. 1996. Characterization of human variable domain antibody fragments against the U1 RNA-associated A protein, selected from a synthetic and patient-derived combinatorial V gene library. Eur. J. Immunol. 26:629-39
101. Huls GA, Heijnen IA, Cuomo ME, Koningsberger JC, Wiegman L, et al. 1999. A recombinant, fully human monoclonal antibody with antitumor activity constructed from phage-displayed antibody fragments. Nat. Biotechnol. 17:276-81
102. Knappik A, Ge L, Honegger A, Pack P, Fischer M, et al. 2000. Fully synthetic human combinatorial antibody libraries (HuCAL) based on modular consensus frameworks and CDRs with randomized trinucleotides. J. Mol. Biol. 296:57-86
103. Foote J, Eisen HN. 1995. Kinetic and affinity limits on antibodies produced during immune responses. Proc. Natl. Acad. Sci. USA 92:1254-56
104. Schier R, McCall A, Adams GP, Marshall KW, Merritt H, et al. 1996. Isolation of picomolar affinity anti-c-erbB-2 single-chain Fv by molecular evolution of the complementarity determining regions in the center of the antibody binding site. J. Mol. Biol. 263:551-67
105. Yang WP, Green K, Pinz-Sweeney S, Briones AT, Burton DR, et al. 1995. CDR walking mutagenesis for the affinity maturation of a potent human anti-HIV-1 antibody into the picomolar range. J. Mol. Biol. 254:392-403
106. Chen Y, Wiesmann C, Fuh G, Li B, Christinger HW, et al. 1999. Selection and analysis of an optimized anti-VEGF antibody: crystal structure of an affinity-matured Fab in complex with antigen. J. Mol. Biol. 293:865-81
107. Deleted in proof
108. Mas MT, Smith KC, Yarmush DL, Aisaka K, Fine RM. 1992. Modeling the anti-CEA antibody combining site by homology and conformational search. Proteins: Struct. Funct. Genet. 14:483-98
109. Kast P, Hilvert D. 1997. 3D structural information as a guide to protein engineering using genetic selection. Curr. Opin. Struct. Biol. 7:470-79
110. Chowdhury PS, Vasmatzis G, Beers R, Lee B, Pastan I. 1998. Improved stability and yield of a Fv-toxin fusion protein by computer design and protein engineering of the Fv. J. Mol. Biol. 281:917-28
111. Berek C, Milstein C. 1987. Mutation drift and repertoire shift in the maturation of the immune response. Immunol. Rev. 96:23-41
112. de Wildt RM, Hoet RMA, van Venrooij WJ, Tomlinson IM, Winter G. 1999. Analysis of heavy and light chain pairings indicates that receptor editing shapes the human antibody repertoire. J. Mol. Biol. 285:895-901
113. Kang AS, Jones TM, Burton DR. 1991. Antibody redesign by chain shuffling from random combinatorial immunoglobulin libraries. Proc. Natl. Acad. Sci. USA 88:11120-23
114. Collet TA, Roben P, O'Kennedy R, Barbas CF, Burton DR, Lerher RA. 1992. A binary plasmid system for shuffling combinatorial antibody libraries. Proc. Natl. Acad. Sci. USA 89:10026-30
115. Marks JD, Griffiths AD, Malmqvist M, Clackson TP, Bye JM, et al. 1992. Bypassing immunization: building high affinity human antibodies by chain shuffling. Bio-Technology 10:779-83
116. Jespers LS, Roberts A, Mahler SM, Winter G, Hoogenboom HR. 1994. Guiding the selection of human antibodies from phage display repertoires to a single epitope of an antigen. Bio-Technology 12: 899-903
117. Thompson J, Pope T, Tung JS, Chan C, Hollis G, et al. 1996. Affinity maturation of a high-affinity human monoclonal antibody against the third hypervariable loop of human immunodeficiency virus: use of phage display to improve affinity and broaden strain reactivity. J. Mol. Biol. 256:77-88
118. Lamminmaki U, Pauperio S, Westerlund-Karlsson A, Karvinen J, Virtanen PL, et al. 1999. Expanding the conformational diversity by random insertions into CDRH2 results in improved anti-estradiol antibodies. J. Mol. Biol. 291:589-602
119. Cadwell RC, Joyce GF. 1992. Randomization of genes by PCR mutagenesis. PCR Methods Appl. 2:28-33
120. Cadwell RC, Joyce GF. 1994. Mutagenic PCR. PCR Methods Appl. 3:S136-40
121. Fromant M, Blanquet S, Plateau P. 1995. Direct random mutagenesis of gene sized DNA fragments using polymerase chain reaction. Anal. Biochem. 224:347-53
122. Vartanian J-P, Henry M, Wain-Hobson S. 1996. Hypermutagenic PCR involving all four transitions and a sizeable proportion of transversions. Nucleic Acids Res. 24:2627-31
123. Zaccolo M, Gherardi E. 1999. The effect of high frequency random mutagenesis on in vitro protein evolution: a study on TEM-1 beta-lactamase. J. Mol. Biol. 285:775-83
124. Gram H, Marconi LA, Barbas CF, Collet TA, Lerner RA, et al. 1992. In vitro selection and affinity maturation of antibodies from a naive combinatorial immunoglobulin library. Proc. Natl. Acad. Sci. USA 89:3576-80
125. Deleted in proof
126. Wedemayer GJ, Patten PA, Wang LH, Schultz PG, Stevens RC. 1997. Structural insights into the evolution of an antibody combining site. Science 276:1665-69
127. Low NM, Holliger PH, Winter G. 1996. Mimicking somatic hypermutation: affinity maturation of antibodies displayed on bacteriophage using a bacterial mutator strain. J. Mol. Biol. 260:359-68
128. Irving RA, Kortt AA, Hudson PJ. 1996. Affinity maturation of recombinant antibodies using E. coli mutator cells. Immunotechnology 2:127-43
129. Wells JA. 1990. Additivity of mutational effects in proteins. Biochemistry 29:8509-17
130. Stemmer WPC. 1994. Rapid evolution of a protein in vitro by DNA shuffling. Nature 370:389-91
131. Zhao H, Giver L, Shao Z, Affholter JA, Arnold F. 1998. Molecular evolution by staggered extension process (StEP) in vitro recombination. Nat. Biotechnol. 16: 258-61
132. Harayama S. 1998. Artificial evolution by DNA shuffling. Trends Biotechnol. 16: 76-82
133. Crameri A, Cwirla S, Stemmer WPC. 1996. Construction and evolution of antibody-phage libraries by DNA shuffling. Nat. Med. 2:100-2
134. Jung S, Honegger A, Pluckthun A. 1999. Selection for improved protein stability by phage display. J. Mol. Biol. 294:163-80
135. Proba K, Worn A, Honegger A, Pluckthun A. 1998. Antibody scFv fragments without disulfide bonds made by molecular evolution. J. Mol. Biol. 275:245-53
136. Leget GA, Czuczman MS. 1998. Use of Rituximab, the new FDA-approved antibody. Curr. Opin. Oncol. 10:548-51
137. Goldenberg MM. 1999. Trastuzumab, a recombinant DNA-derived humanized monoclonal antibody, a novel agent for the treatment of metastatic breast cancer. Clin.Ther. 21:309-18
138. Chester KA, Hawkins RE. 1995. Clinical issues in antibody design. Trends Biotechnol. 13:294-300
139. Boulianne GL, Hozumi N, Shulman MJ. 1984. Production of functional chimaeric mouse/human antibody. Nature 312:643-46
140. Morrison SL, Johnson MJ, Herzenberg LA, Oi VT. 1984. Chimeric antibody molecules: mouse antigen binding domains with human constant region domains. Proc. Natl. Acad. Sci. USA 81: 6851-55
141. Knight DM, Wagner C, Jordan R, McAleer MF, DeRita R, et al. 1995. The immunogenicity of the 7E3 murine monoclonal Fab antibody fragment variable region is dramatically reduced in humans by substitution of human for murine constant regions. Mol. Immunol. 32:1271-81
142. Adair JR. 1992. Engineering antibodies for therapy. Immunol. Rev. 130:5-39
143. Riechmann L, Clark M, Waldmann H, Winter G. 1988. Reshaping human antibodies for therapy. Nature 332:323-27
144. Jones PT, Dear PH, Foote J, Neuberger MS, Winter G. 1986. Replacing the complementarity determining regions in a human antibody with those from a mouse. Nature 321:522-25
145. Banfield MJ, King DJ, Mountain A, Brady RL. 1997. VL:VH domain rotations in engineered antibodies: crystal structures of the Fab fragments from two murine anti-tumor antibodies and their engineered human constructs. Proteins: Struct. Funct. Genet. 29:161-71
146. Foote J, Winter G. 1992. Antibody framework residues affecting the conformation of the hypervariable loops. J. Mol. Biol. 224:487-99
147. Mateo C, Moreno E, Amour K, Lombardero J, Harris W, et al. 1997. Humanization of a mouse monoclonal antibody that blocks the epidermal growth factor receptor: recovery of antagonistic activity. Immunotechnology 3:71-81
148. Padlan EA. 1991. A possible procedure for reducing the immunogenicity of antibody variable domains while preserving their ligand-binding properties. Mol. Immunol. 28:489-98
149. Delagrave S, Catalan J, Sweet C, Drabik G, Henry A, et al. 1999. Effects of humanization by variable domain resurfacing on the antiviral activity of a single-chain antibody against respiratory syncytial virus. Protein Eng. 12:357-62
150. Baca M, Presta LG, O'Connor SJ, Wells JA. 1997. Antibody humanization using monovalent phage display. J. Biol. Chem. 272:10678-84
151. Rader C, Cheresh DA, Barbas CF, 3rd. 1998. A phage display approach for rapid antibody humanization: designed combinatorial V gene libraries. Proc. Natl. Acad. Sci. USA 95:8910-15
152. Bruggemann M, Taussig MJ. 1997. Production of human antibody repertoires in transgenic mice. Curr. Opin. Biotechnol. 8:455-58
153. Fishwild DM, O'Donnell SL, Bengoechea T, Hudson DV, Harding F, et al. 1996. High-avidity human IgG kappa monoclonal antibodies from a novel strain of minilocus transgenic mice. Nat. Biotechnol. 14:845-51
154. Mendez M, Green L, Corvalan J, Jia X-C, Maynard-Currie C, et al. 1997. Functional transplant of megabase human immunoglobulin loci recapitulates human antibody response in mice. Nat. Genet. 15:146-56
155. Yang XD, Jia XC, Corvalan JR, Wang P, Davis CG, et al. 1999. Eradication of established tumors by a fully human monoclonal antibody to the epidermal growth factor receptor without concomitant chemotherapy. Cancer Res. 59:1236-43
156. Yang XD, Corvalan JR, Wang P, Roy CM, Davis CG. 1999. Fully human anti-interleukin-8 monoclonal antibodies: potential therapeutics for the treatment of inflammatory disease states. J. Leukocyte Biol. 66:401-10
157. Iliades P, Kortt AA, Hudson PJ. 1997. Triabodies: single chain Fv fragments without a linker form trivalent trimers. FEBS Lett. 409:437-41
158. Kortt AA, Lah M, Oddie GW, Gruen CL, Burns JE, et al. 1997. Single-chain Fv fragments of anti-neuraminidase antibody NC10 containing five-and ten-residue linkers form dimers and with zero-residue linker a trimer. Protein Eng. 10: 423-33
159. Le Gall F, Kipriyanov SM, Moldenhauer G, Little M. 1999. Di-, tri-and tetrameric single chain Fv antibody fragments against human CD19: effect of valency on cell binding. FEBS Lett. 453: 164-68
160. Pluckthun A, Pack P. 1997. New protein engineering approaches to multivalent and bispecific antibody fragments. Immunotechnology 3:83-105
161. Perisic O, Webb PA, Holliger P, Winter G, Williams RL. 1994. Crystal structure of a diabody, a bivalent antibody fragment. Structure 2:1217-26
162. Lawrence LJ, Kortt AA, Iliades P, Tulloch PA, Hudson PJ. 1998. Orientation of antigen binding sites in dimeric and trimeric single chain Fv antibody fragments. FEBS Lett. 425:479-84
163. Pei XY, Holliger P, Murzin A, Williams RL. 1997. The 2.0 Å resolution crystal structure of a trimeric antibody fragment with non-cognate Vh/Vl domain pairs shows a rearrangement of Vh CDR3. Proc. Natl. Acad. Sci. USA 94:9637-42
164. Muller KM, Arndt KM, Pluckthun A. 1998. Model and simulation of multi-valent binding to fixed ligands. Anal. Biochem. 261:149-58
165. Wu AM, Chen W, Raubitschek A, Williams LE, Neumaier M, et al. 1996. Tumor localization of anti-CEA single-chain Fvs: improved tumor targeting by non-covalent dimers. Immunotechnology 2:21-36
166. Adams GP, Schier R, McCall AM, Crawford RS, Wolf EJ, et al. 1998. Prolonged in vivo tumour retention of a human diabody targeting the extracellular domain of human HER2/neu. Br. J. Cancer 77: 1405-12
167. Kipriyanov SM, Little M, Kropshofer H, Breitling F, Gotter S, et al. 1996. Affinity enhancement of a recombinant antibody: formation of complexes with multiple valency by a single-chain Fv fragment-core streptavidin fusion. Protein Eng. 9:203-11
168. Hudson PJ. 1999. Recombinant antibody constructs in cancer therapy. Curr. Opin. Immunol. 11:548-57
169. Trill JJ, Schatzman AR, Ganguly S. 1995. Production of monoclonal antibodies in COS and CHO cells. Curr. Opin. Biotechnol. 6:553-60
170. Khoudi H, Laberge S, Ferullo JM, Bazin R, Darveau A, et al. 1999. Production of a diagnostic monoclonal antibody in perennial alfalfa plants. Biotechnol. Bioeng. 64:135-43
171. Skerra A, Pluckthun A. 1988. Assembly of a functional immunoglobulin Fv fragment in Escherichia coli. Science 240: 1038-41
172. Better M, Chang CP, Robinson RR, Horwitz A. 1988. Escherichia coli expression of an active chimeric antibody fragment. Science 240:1041-43
173. Skerra A. 1993. Bacterial expression of immunoglobulin fragments. Curr. Opin. Immunol. 5:256-62
174. Somerville JE Jr, Goshorn SC, Fell HP, Darveau RP. 1994. Bacterial aspects associated with the expression of a single-chain antibody fragment in Escherichia coli. Appl. Microbiol. Biotechnol. 42:595-603
175. Clark MA, Hammond FR, Papaioannou A, Hawkins NJ, Ward RL. 1997. Regulation and expression of human Fabs under the control of the Escherichia coli arabinose promoter, pBAD. Immunotechnology 3:217-26
176. Skerra A, Pluckthun A. 1991. Secretion and in vivo folding of the Fab fragment of the antibody McPC603 in Escherichia coli: influence of disulphides and cis-prolines. Protein Eng. 4:971-79
177. Bothmann H, Pluckthun A. 1998. Selection for a periplasmic factor improving phage display and functional periplasmic expression. Nat. Biotechnol. 16:376-80
178. Humphreys DP, Weir N, Lawson A, Mountain A, Lund PA. 1996. Co-expression of human protein disulphide isomerase (PDI) can increase the yield of an antibody Fab' fragment expressed in Escherichia coli. FEBS Lett. 380:194-97
179. Hayhurst A, Harris WJ. 1999. Escherichia coli skp chaperone coexpression improves solubility and phage display of single-chain antibody fragments. Protein Exp. Purif. 15:336-43
180. Duenas M, Ayala M, Vazquez J, Ohlin M, Soderlind E, et al. 1995. A point mutation in a murine immunoglobulin V-region strongly influences the antibody yield in Escherichia coli. Gene 158:61-66
181. Forsberg G, Forsgren M, Jaki M, Norin M, Sterky C, et al. 1997. Identification of framework residues in a secreted recombinant antibody fragment that controls production level and localization in Escherichia coli. J. Biol. Chem. 272:12430-36
182. Nieba L, Honegger A, Krebber C, Pluckthun A. 1997. Disrupting the hydrophobic patches at the antibody variable/constant domain interface: improved in vivo folding and physical characterization of an engineered scFv fragment. Protein Eng. 10:435-44
183. Kipriyanov SM, Moldenhauer G, Martin AC, Kupriyanova OA, Little M. 1997. Two amino acid mutations in an anti-human CD3 single chain Fv antibody fragment that affect the yield on bacterial secretion but not the affinity. Protein Eng. 10:445-53
184. Jung S, Pluckthun A. 1997. Improving in vivo folding and stability of a single-chain Fv antibody fragment by loop grafting. Protein Eng. 10:959-66
185. Worn A, Pluckthun A. 1999. Different equilibrium stability behavior of ScFv fragments: identification, classification, and improvement by protein engineering. Biochemistry 38:8739-50
186. Buchner J, Rudolph R. 1991. Renaturation, purification and characterization of recombinant Fab-fragments produced in Escherichia coli. Bio-Technology 9:157-62
187. Maeda Y, Yamada H, Ueda T, Imoto T. 1996. Effect of additives on the renaturation of reduced lysozyme in the presence of 4 M urea. Protein Eng. 9:461-65
188. Buchner J, Pastan I, Brinkmann U. 1992. A method for increasing the yield of properly folded recombinant fusion proteins: single-chain immunotoxins from renaturation of bacterial inclusion bodies. Anal. Biochem. 205:263-70
189. Rudolph R, Lilie H. 1996. In vitro folding of inclusion body proteins. FASEB J. 10:49-56
190. de Bernardez Clark E. 1998. Refolding of recombinant proteins. Curr. Opin. Biotech. 9:157-63
191. Lilie H, Schwarz E, Rudolph R. 1998. Advances in refolding of proteins produced in E. coli. Curr. Opin. Biotechnol. 9:497-501
192. Derman AI, Prinz WA, Belin D, Beckwith J. 1993. Mutations that allow disulfide bond formation in the cytoplasm of Escherichia coli. Science 262:1744-47
193. Proba K, Ge L, Pluckthun A. 1995. Functional antibody single-chain fragments from the cytoplasm of Escherichia coli: influence of thioredoxin reductase (TrxB). Gene 159:203-7
194. He M, Hamon M, Liu H, Kang A, Taussig MJ. 1995. Functional expression of a single-chain anti-progesterone antibody fragment in the cytoplasm of a mutant Escherichia coli. Nucleic Acids Res. 23: 4009-10
195. Bessette PH, Aslund F, Beckwith J, Georgiou G. 1999. Efficient folding of proteins with multiple disulfide bonds in the Escherichia coli cytoplasm. Proc. Natl. Acad. Sci. USA 96:13703-8
196. Cattaneo A, Biocca S. 1999. The selection of intracellular antibodies. Trends Biotechnol. 17:115-21
197. Worn A, Pluckthun A. 1998. An intrinsically stable antibody scFv fragment can tolerate the loss of both disulfide bonds and fold correctly. FEBS Lett. 427:357-61
198. Proba K, Honegger A, Pluckthun A. 1997. A natural antibody missing a cysteine in VH: consequences for thermodynamic stability and folding. J. Mol. Biol. 265:161-72
199. Martineau P, Jones P, Winter G. 1998. Expression of an antibody fragment at high levels in the bacterial cytoplasm. J. Mol. Biol. 280:117-27
200. Visintin M, Tse E, Axelson H, Rabbitts TH, Cattaneo A. 1999. Selection of antibodies for intracellular function using a two-hybrid in vivo system. Proc. Natl. Acad. Sci. USA 96:11723-28
201. Ohage E, Steipe B. 1999. Intrabody construction and expression: I. The critical role of VL domain stability. J. Mol. Biol. 291:1119-28
202. Ohage EC, Wirtz P, Barnikow J, Steipe B. 1999. Intrabody construction and expression: II. A synthetic catalytic Fv fragment. J. Mol. Biol. 291:1129-34
203. Whittum-Hudson JA, An LL, Saltzman WM, Prendergast RA, MacDonald AB. 1996. Oral immunization with an anti-idiotypic antibody to the exoglycolipid antigen protects against experimental Chlamydia trachomatis infection. Nat. Med. 2:1116-21
204. Harris B. 1999. Exploiting antibody-based technologies to manage environmental pollution. Trends Biotechnol. 17: 290-96
205. Mousli M, Devaux C, Rochat H, Goyffon M, Billiad P. 1999. A recombinant single-chain antibody fragment that neutralizes toxin II from the venom of the scorpion Androctonus australis hector. FEBS Lett. 442:183-88
206. Barbas CF III, Hu D, Dunlop N, Sawyer L, Cababa D, et al. 1994. In vitro evolution of a neutralizing human antibody to human immunodeficiency virus type 1 to enhance affinity and broaden strain cross-reactivity. Proc. Natl. Acad. Sci. USA 91:3809-13
207. Gauduin MC, Parren PW, Weir R, Barbas CF, Burton DR, et al. 1997. Passive immunization with a human monoclonal antibody protects hu-PBL-SCID mice against challenge by primary isolates of HIV-1. Nat. Med. 3:1389-93
208. Marasco W. 1995. Intracellular antibodies (intrabodies) as research reagents and therapeutic molecules for gene therapy. Immunotechnology 1:1-19
209. Poul MA, Marks JD. 1999. Targeted gene delivery to mammalian cells by filamentous bacteriophage. J. Mol. Biol. 288: 203-11
210. Marasco W, Haseltine WA, Chen S. 1993. Design, intracellular exression, and activity of a human anti-human immunodeficiency virus type I gp120 single-chain antibody. Proc. Natl. Acad. Sci. USA 90:7889-93
211. Richardson JH, Sodroski JG, Waldmann TA, Marasco WA. 1995. Phenotypic knockout of the high-affinity human interleukin 2 receptor by intracellular single-chain antibodies against the alpha subunit of the receptor. Proc. Natl. Acad. Sci. USA 92:3137-41
212. Beerli RR, Weis W, Hynes NE. 1994. Intracellular expression of single chain antibodies reverts ErbB-2 transformation. J. Biol. Chem. 289:23931-36
213. Begent RHJ. 1996. Clinical evidence of efficient tumor targeting based on single-chain Fv antibody selected from a combinatorial library. Nat. Med. 2:979-84
214. Waldmann TA. 1991. Monoclonal antibodies in diagnosis and therapy. Science 252:1657-62
215. George AJ, Jamar F, Tai MS, Heelan BT, Adams GP, et al. 1995. Radiometal labeling of recombinant proteins by a genetically engineered minimal chelation site: technetium-99m coordination by single-chain Fv antibody fusion proteins through a C-terminal cysteinyl peptide. Proc. Natl. Acad. Sci. USA 92:8358-62
216. Das C, Kulkarni PV, Constantinescu A, Antich P, Blattner FR, et al. 1992. Recombinant antibody-metallothionein: design and evaluation for radioimmunoimaging. Proc. Natl. Acad. Sci. USA 89:9749-53
217. Waibel R, Alberto R, Willuda J, Finnern R, Schibli R, et al. 1999. Stable one-step technetium-99m labeling of histagged recombinant proteins with a novel Tc(I)-carbonyl complex. Nat. Biotechnol. 17:897-901
218. Cragg MS, French RR, Glennie MJ. 1999. Signaling antibodies in cancer therapy. Curr. Opin. Immunol. 10:541-47
219. Pegram M, Hsu S, Lewis G, Pietras R, Beryt M, et al. 1999. Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers. Oncogene 18:2241-51
220. DeNardo SJ, Kroger LA, DeNardo GL. 1999. A new era for readiolabeled antibodies in cancer? Curr. Opin. Immunol. 10:563-69
221. Lopes de Menezes DE, Pilarski LM, Allen TM. 1998. In vitro and in vivo targeting of immunoliposomal doxorubicin to human B-cell lymphoma. Cancer Res. 58:3320-30
222. Trail PA, Bianchi AB. 1999. Monoclonal antibody drug conjugates in the treatment of cancer. Curr. Opin. Immunol. 11:584-88
223. Bera TK, Viner J, Brinkmann E, Pastan I. 1999. Pharmacokinetics and antitumor activity of a bivalent disulfide-stabilized Fv immunotoxin with improved antigen binding to erbB2. Cancer Res. 59:4018-22
224. Pai LH, Pastan I. 1998. Clinical trials with Pseudomonas exotoxin immunotoxins. Curr. Top. Microbiol. Immunol. 234: 83-96
225. Rosenblum MG, Shawver LK, Marks JW, Bringk J, Cheung L, et al. 1999. Recombinant immunotoxins directed against the c-erb-2/HER2/neu oncogene product: in vitro cytotoxicity, pharmacokinatics, and in vivo efficacy studies in xenograft models. Clin. Cancer Res. 5:865-74
226. Bagshawe KD, Sharma SK, Burke PJ, Melton RG, Knox RJ. 1999. Developments with targeted enzymes in cancer therapy. Curr. Opin. Immunol. 11:579-83
227. Zhu Z, Lewis GD, Carter P. 1995. Engineering high affinity humanized anti-p185(HER2)/anti-CD3 bispecific F(ab′)2 for efficient lysis of p185(HER2) overexpressing tumor cells. Int. J. Cancer 62: 319-24
228. Keler T, Graziano RF, Mandai A, Wallace PK, Fisher J, et al. 1997. Bispecific antibody-dependent cellular cytotoxicity of HER2/neu-overexpressing tumor cells by Fc-gamma receptor type I-expressing cells. Cancer Res. 57:4008-14
229. Helfrich W, Kroesen BJ, Roovers RC, Westers L, Molema G, et al. 1998. Construction and characterization of a bispecific diabody for retargeting T cells to human carcinomas. Int. J. Cancer 76:232-39
230. Mendelsohn J. 1997. Epidermal growth factor receptor inhibition by a monoclonal antibody as anticancer therapy. Clin. Cancer Res. 3:2703-7
231. Jain RK. 1999. Transport of molecules, particles, and cells in solid tumors. Annu. Rev. Biomed. Eng. 1:241-63
232. Milenic DE, Yokota T, Filpula DR, Finkelman MAJ, Dodd SW, et al. 1991. Construction, binding properties, metabolism, and tumor-targeting of a single-chain Fv derived from the pancarcinoma monoclonal antibody CC49. Cancer Res. 51:6363-71
233. Adams GP, Schier R, Marshall K, Wolf EJ, McCall AM, et al. 1998. Increased affinity leads to improved selective tumor delivery of single-chain Fv antibodies. Cancer Res. 58:485-90
234. Baxter LT, Zhu H, Mackensen DG, Butler WF, Jain RK. 1995. Biodistribution of monoclonal antibodies: scale-up from mouse to human using a physiologically based pharmacokinetic model. Cancer Res. 55:4611-22
235. Viti F, Tarli L, Giovannoni L, Zardi L, Neri D. 1999. Increased binding affinity and valence of recombinant antibody fragments lead to improved targeting of tumoral angiogenesis. Cancer Res. 59:347-52